Application of Endoscopy-based Tailored Therapy in the Eradication of Helicobacter pylori

张灵云,宋志强,周丽雅,张建中,丁钰

DOI: https://doi.org/10.3969/j.issn.1009-6604.2015.06.005

2015-01-01

Abstract:Objective To determine the eradication efficacy , safety, and compliance of endoscopy-based tailored therapy in the initial and retreated patients with Helicobacter pylori infection. Methods Between May 2013 and June 2014, patients with dyspepsia (18-70 years old) diagnosed as having infection of Helicobacter pylori under gastroscopy in our hospital were recruited into the study.Gastric mucosa specimens taken with the gastroscopy were cultured for Helicobacter pylori and then antibiotics sensitivity and cytochrome P450 isoenzyme 2C19 genotype were detected .Medications for tailored therapy included amoxicillin and were adjusted based on clarithromycin sensitivity ( clarithromycin or tinidazole ) and cytochrome P450 isoenzyme 2C19 genotype ( rabeprazole or esomeprazole ) .Eradication status was assessed 4-12 weeks after treatment with urea breath test . Results A total of 318 initially-treated and 62 retreated cases of infection of Helicobacter pylori had successful culture of Helicobacter pylori and the culture success rates were 90.9% (318/350) and 91.2% (62/68), respectively.These cases were included in the intention-to-treat analyses. Finally 298 initially-treated and 59 retreated cases completed the treatment and follow-up and were included in the per-protocol analyses.The eradication rates of endoscopy-based tailored therapy in the initially-treated and the retreated cases were 88.7%(95%confidence interval, 85.2%-92.1%) and 75.8% (95% confidence interval,65.1%-86.5%) in intention-to-treat analyses, and 93.3%(95%confidence interval ,89.9%-96.0%) and 79.7%(95%confidence interval ,69.7%-89.7%) in per-protocol analyses . The rates of adverse effects were 22.0% (70/318) and 33.9% (21/62) in the two groups.The compliance of the two groups was 94.3%(300/318) and 95.2%(59/62), respectively. Conclusion Endoscopy-based tailored therapy has a satisfactory eradication efficacy in initially-treated patients with Helicobacter pylori infection, but a poor eradication efficacy in retreated patients .